Back to News
Market Impact: 0.25
Amgen Drops 10% on a Trial It Didn't Even Run
Source: marketbeat.com
Corporate EarningsHealthcare & Biotech
Amgen delivered a strong earnings report on Aug. 4, according to the article. No revenue, EPS, guidance, or other financial magnitudes were provided to assess the extent of the earnings outperformance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
AMGN0.65
More News
- +52%, +39%, +22%: Our AI just called these blue-chip breakouts
- NOW 55% OFF: Rattled by Fed headlines? Meet the AI doubled the market’s return
- FIRE SALE | InvestingPro for less than $8/month (all features included in the app)
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- Asian stocks surge as Anthropic IPO lifts sentiment ahead of earnings, central banks